🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Herbert H. Loong

Chinese University of Hong Kong

ORCID: 0000-0002-6607-1106

Also affiliated with Prince of Wales Hospital, Dana-Farber Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile
0.452Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

35P Final data from phase I/II LIBRETTO-001 trial of selpercatinib in RET fusion-positive non-small cell lung cancer

ESMO Open(2024)10.1016/j.esmoop.2024.102614
Top 42%
0.452DataRank
Top 42%8 citations

Alexander Drilon, Benjamin Solomon, Pascale Tomasini, Herbert H. Loong, Filippo de Braud +7 more

Papers

Driven by 7 papers — median percentile 29. Top paper: “First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC”.

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

New England Journal of Medicine(2023)10.1056/nejmoa2309457
N/A
4.6DataRank · unranked
218 citations

Benjamin Solomon, Herbert H. Loong, Keunchil Park, M. Pérol, Edurne Arriola +19 more

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0800
N/A
3.5DataRank · unranked
140 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, Dwight H. Owen, Byoung Chul Cho +16 more

35P Final data from phase I/II LIBRETTO-001 trial of selpercatinib in RET fusion-positive non-small cell lung cancer

ESMO Open(2024)10.1016/j.esmoop.2024.102614
Top 42%
0.452DataRank
Top 42%8 citations

Alexander Drilon, Benjamin Solomon, Pascale Tomasini, Herbert H. Loong, Filippo de Braud +7 more

Supplementary Table S2 from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

(2023)10.1158/1078-0432.22481301
Top 100%
0DataRank
Top 100%0 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non–Small-Cell Lung Cancer

Clinical Lung Cancer(2023)10.1016/j.cllc.2023.12.001
N/A
0DataRank · unranked
5 citations

Alexander Drilon, Chao‐Hua Chiu, Herbert H. Loong, Salvatore Siena, Maciej Krzakowski +5 more

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Nature Reviews Clinical Oncology(2021)10.1038/s41571-021-00487-z
N/A
0DataRank · unranked
140 citations

Justin F. Gainor, Aparna Hegde, Alison M. Schram, Giuseppe Curigliano, Sumanta K. Pal +19 more

Data from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

(2023)10.1158/1078-0432.c.6530655.v1
N/A
0DataRank · unranked
0 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho +16 more